Key Points
- CFO Lee Kalowski sold 9,072 shares on Dec. 2 at an average of $3.46 for roughly $31,389, reducing his ownership by 18.51% to 39,938 shares.
- Q32 Bio shares were trading around $3.53 (market cap ~$43.4M); the company posted a (-$0.60) EPS last quarter—beating estimates by $0.79—and analysts have a consensus "Hold" rating with a $12.17 target.
- Institutional investors own about 31.3% of the stock, and several funds (including Monaco, Goldman Sachs, AQR and Nuveen) have recently added or initiated positions, indicating some institutional interest despite insider selling.
Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) CFO Lee Kalowski sold 9,072 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $3.46, for a total transaction of $31,389.12. Following the completion of the transaction, the chief financial officer owned 39,938 shares in the company, valued at $138,185.48. This represents a 18.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Q32 Bio Price Performance
Shares of NASDAQ:QTTB traded down $0.09 during trading on Friday, hitting $3.53. 197,019 shares of the company were exchanged, compared to its average volume of 1,263,479. The stock has a market capitalization of $43.42 million, a P/E ratio of -1.02 and a beta of 0.23. Q32 Bio Inc. has a 12-month low of $1.35 and a 12-month high of $28.06. The firm's 50 day moving average price is $2.64 and its 200-day moving average price is $2.12.
Q32 Bio (NASDAQ:QTTB - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($1.39) by $0.79. As a group, equities research analysts anticipate that Q32 Bio Inc. will post -12.32 EPS for the current year.
Wall Street Analyst Weigh In
QTTB has been the topic of a number of research analyst reports. Wall Street Zen upgraded Q32 Bio from a "sell" rating to a "hold" rating in a research report on Sunday, October 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Q32 Bio in a research note on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Q32 Bio presently has a consensus rating of "Hold" and a consensus target price of $12.17.
Get Our Latest Stock Report on Q32 Bio
Institutional Investors Weigh In On Q32 Bio
Hedge funds have recently made changes to their positions in the business. Monaco Asset Management SAM grew its holdings in shares of Q32 Bio by 17.1% during the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company's stock worth $882,000 after buying an additional 86,486 shares during the last quarter. Nuveen LLC purchased a new stake in Q32 Bio during the 1st quarter valued at approximately $92,000. Jane Street Group LLC acquired a new stake in Q32 Bio during the 2nd quarter worth approximately $69,000. Goldman Sachs Group Inc. grew its stake in shares of Q32 Bio by 140.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company's stock valued at $73,000 after purchasing an additional 25,953 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Q32 Bio in the 1st quarter valued at approximately $68,000. Institutional investors and hedge funds own 31.32% of the company's stock.
Q32 Bio Company Profile
(
Get Free Report)
Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
